Bristol Myers Squibb’s Admilparant Meets Phase 3 Trial Primary Endpoint
Bristol Myers Squibb said its 52-week phase 3 trial of twice-daily admilparant in adults with idiopathic pulmonary fibrosis met its primary endpoint.
The phase 3 trial evaluated two dose levels of admilparant taken twice daily for 52 weeks against a placebo. The 60-milligram dose demonstrate…